10-Q: Cannabist Co. Q2 2025: Revenue Plunges, Losses Widen

The Cannabist Company Holdings Inc. reported a significant decline in Q2 2025 revenue and a widening net loss, driven by divestitures and operational challenges.

Summary

• Net loss for the three months ended June 30, 2025, was $77.386 million, a 467% increase from $13.643 million in the prior year period.
• Net loss for the six months ended June 30, 2025, was $109.592 million, a 127% increase from $48.211 million in the prior year period.
• Revenue for the three months ended June 30, 2025, decreased by 31% to $86.350 million from $125.190 million in the prior year period.
• Revenue for the six months ended June 30, 2025, decreased by 30% to $173.790 million from $247.801 million in the prior year period.
• Gross profit for the three months ended June 30, 2025, fell by 64% to $17.153 million from $48.052 million.
• Gross profit for the six months ended June 30, 2025, fell by 49% to $46.438 million from $90.589 million.
• Operating results shifted from a profit of $8.006 million in Q2 2024 to an operating loss of $15.837 million in Q2 2025.
• Adjusted EBITDA decreased to $8.483 million in Q2 2025 from $17.537 million in Q2 2024, and to $16.776 million in H1 2025 from $32.843 million in H1 2024.
• Cash and restricted cash at June 30, 2025, was $18.591 million, down from $37.930 million at the beginning of the period.
• Total assets decreased to $563.838 million at June 30, 2025, from $696.173 million at December 31, 2024.
• Total equity was negative $138.846 million at June 30, 2025, worsening from negative $30.059 million at December 31, 2024.
• Completed a debt restructuring (2025 Debt Transaction) on May 29, 2025, exchanging existing Senior Notes for new 9.25% Senior Secured Notes due December 31, 2028, and 9.0% convertible notes.
• Issued 118,209,105 warrants to shareholders as part of the 2025 Debt Transaction.
• Divested several non-core assets, including Utah operations, Arizona operations, Eastern Virginia operations, Florida Business, Milford II cultivation property, North Hollywood dispensary, DeSoto dispensary, THC dispensary, and Florida paper license.
• Entered into definitive agreements to divest a Balboa, CA manufacturing facility for approximately $738 thousand and three dispensaries in Pennsylvania for $10 million.

Sentiment

Score: 2

Explanation: The company reported substantial declines across key financial metrics including revenue, gross profit, and net loss, indicating significant operational challenges. While debt maturities were extended, the overall financial health has deteriorated, with negative equity and continued cash burn from operations. The ongoing divestitures suggest a need to raise capital or streamline operations due to financial distress.

Positives

• Successfully completed the 2025 Debt Transaction on May 29, 2025, extending debt maturities to December 31, 2028, providing financial flexibility.
• Selling, general, and administrative expenses decreased by 18% ($7.056 million) in Q2 2025 and 25% ($23.078 million) in H1 2025, indicating some cost control.
• Successful divestiture of non-core assets generated cash proceeds and reduced liabilities, streamlining operations.
• Achieved early settlement of the Eastern Virginia seller note for a $10.0 million one-time payment, improving liquidity.
• Approved a Transaction Bonus Plan for key employees, potentially incentivizing future strategic transactions and divestitures.

Negatives

• Revenue declined significantly by 31% in Q2 2025 and 30% in H1 2025, primarily due to divestitures and a net decline in existing operations.
• Gross profit decreased substantially by 64% in Q2 2025 and 49% in H1 2025, reflecting lower revenues and inventory impairments.
• Net loss widened considerably by 467% in Q2 2025 and 127% in H1 2025, indicating a deteriorating financial performance.
• Operating results shifted from a profit to a loss in Q2 2025, highlighting operational challenges.
• Adjusted EBITDA decreased by 51.6% in Q2 2025 and 48.9% in H1 2025, signaling reduced operational efficiency.
• Cash and restricted cash decreased by $19.339 million in H1 2025, indicating continued cash burn from operations.
• Total equity is significantly negative at $(138.846) million and worsened from December 31, 2024.
• Inventory write-downs due to restructuring efforts amounted to $9.319 million in Q2 2025 and $10.571 million in H1 2025.
• Interest expense, net, increased by $4.969 million in Q2 2025 and $5.089 million in H1 2025.
• Incurred a loss on disposal group of $4.089 million in Q2 2025 and $7.327 million in H1 2025.
• Recorded a loss on early extinguishment of note of $3.227 million in H1 2025.
• Income tax expense increased significantly to $43.221 million in Q2 2025 from $9.642 million in Q2 2024.

Risks

• Impact of corporate restructuring activities, including debt restructuring.
• Marijuana remains illegal under federal law, posing regulatory and operational challenges.
• Application of anti-money laundering laws and regulations to the company.
• Potential legal, regulatory, or political changes to the cannabis industry.
• Challenges in accessing public and private capital.
• Risk of unfavorable publicity or consumer perception of the cannabis industry.
• Impact of laws, regulations, and guidelines on operations.
• Impact of Section 280E of the U.S. Internal Revenue Code of 1986, which disallows certain business deductions for cannabis companies.
• Impact of state laws pertaining to the cannabis industry, which vary and can change.
• Reliance on key inputs, suppliers, and skilled labor, which can be subject to disruption.
• Difficulty in accurately forecasting sales in a rapidly evolving market.
• Constraints on marketing products due to regulatory restrictions.
• Potential for cyber-attacks and security breaches impacting data and operations.
• Limitations on net operating loss and other tax attributes.
• Impact of changes in tax laws on financial performance.
• Volatility of the market price of common shares.
• Reliance on management and the potential impact of their departure or inability to perform.
• Ongoing litigation, specifically appeals by Murchinson Ltd. regarding the 2025 Debt Transaction.
• Uncertainty regarding future results and financial projections.
• Impact of global financial conditions on business operations and access to capital.
• Inability to retain or hire necessary qualified personnel due to challenging financial conditions.

Future Outlook

The company expects to continue meeting its short-term obligations based on current business operations and working capital. It aims to focus on profitability and remains opportunistic for growth through expansion or acquisition, acknowledging that cash flow requirements and obligations could materially change. Future financial results are subject to significant fluctuations from sales volume growth in new and existing markets, the ability to control operating expenses, and changes in the regulatory environment.

Management Comments

• "Our future financial results are subject to significant potential fluctuations caused by, among other things, growth of sales volume in new and existing markets and our ability to control operating expenses."
• "In addition, our financial results may be impacted significantly by changes to the regulatory environment in which we operate, on a local, state, and federal level."
• "We are currently meeting our obligations and are earning revenues from our operations. However, we have sustained losses since inception and may require additional capital in the future."
• "We estimate that based on our current business operations and working capital, we will continue to meet our obligations in the short term."
• "As we continue to focus on profitability, we endeavor to remain opportunistic on growth through expansion or acquisition, therefore our cash flow requirements and obligations could materially change."

Industry Context

The company operates in the highly regulated U.S. cannabis industry, which faces challenges such as the federal illegality of marijuana and the impact of Section 280E of the U.S. Internal Revenue Code. As one of the original multi-state providers, the company is streamlining operations through divestitures of non-core assets, a trend observed among some multi-state operators (MSOs) in a challenging market. The industry is subject to significant changes at local, state, and federal levels, which can impact the company's ability to grow profitably or open new markets.

Management Changes

Corporate Governance

Legal Proceedings

• Murchinson Ltd. filed an application in the Ontario Superior Court of Justice (Commercial List) on March 27, 2025, opposing the 2025 Debt Transaction, claiming it was oppressive, breach of contract, and civil conspiracy, seeking unspecified damages and costs.
• The Court ruled in favor of the Company on May 21, 2025, and the 2025 Debt Transaction was closed.
• Murchinson Ltd. has filed appeals to the Court of Appeal for Toronto that are currently pending.

Stakeholder Impact

• Shareholders: Experienced significant dilution from warrant issuance (118,209,105 warrants) and common shares issued for convertible notes (19,328,305 shares). Negative equity and widening losses indicate erosion of shareholder value. Debt restructuring provides short-term relief but does not address underlying profitability issues.
• Employees: Key employees are eligible for a Transaction Bonus Plan, potentially incentivizing them for strategic transactions. However, restructuring efforts and divestitures may lead to job reductions in divested operations. The President's employment agreement terms were amended.
• Creditors/Noteholders: Existing noteholders exchanged debt for new notes with extended maturities (2028 Notes and 2028 Convertible Notes), providing some stability but also extending their exposure. The new notes are secured by a first-priority security interest.
• Customers: Divestitures of dispensaries and cultivation facilities in various states (Utah, Arizona, Virginia, Florida, California, Pennsylvania) will impact customer access to the company's products in those regions.
• Suppliers: Reduced operations due to divestitures may lead to decreased demand for supplies from certain vendors.

Next Steps

• Continue efforts towards profitability.
• Remain opportunistic on growth through expansion or acquisition.
• Amortize debt financing costs over the term of the 2028 Notes and 2028 Convertible Notes.
• Monitor pending appeals by Murchinson Ltd. in the Court of Appeal for Toronto regarding the 2025 Debt Transaction.
• Complete the divestiture of the Balboa, CA manufacturing facility (entered into definitive agreements on July 2, 2025).
• Complete the divestiture of three dispensaries in Pennsylvania (entered into definitive agreements on August 4, 2025).
• Potentially receive an additional $2.5 million contingent payment from Florida license divestiture in the event of an adult use program in the state.

Key Dates

Recommendation

The company exhibits severe financial distress with substantial revenue declines, widening net losses, and negative equity. While debt maturities have been extended, the core business continues to burn cash from operations, and profitability remains elusive. The ongoing divestitures, while generating some cash, indicate a shrinking operational footprint and do not fundamentally address the underlying financial challenges. The significant dilution from warrant issuance and the pending legal appeals add further uncertainty. Given the deteriorating financial performance and the challenging industry environment, the stock presents a high risk with limited upside potential in the near term.

Keywords

Cannabis, Marijuana, Multi-state operator, MSO, Dispensary, Cultivation, Wholesale, SEC filing, 10-Q, Financial results, Debt restructuring, Divestitures, Asset sales, Corporate governance, Risk factors, The Cannabist Company, CBSTF